Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC16A1 | P53985 | 19/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 13/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 9/20 | 1.00 |
| ▸ | SLC16A3 | O15427 | 1/20 | 1.00 |
| ▸ | SLC16A7 | O60669 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3826454 | 1.00 | SLC16A1 (1.00) | SLC16A1CYP2C9CYP3A4SLC16A3SLC16A7 | |
| SCHEMBL23958362 | 1.00 | SLC16A1 (1.00) | SLC16A1CYP2C9CYP3A4SLC16A3SLC16A7 | |
| SCHEMBL3827690 | 0.93 | SLC16A1 (0.87) | SLC16A1CYP2C9CYP3A4SLC16A3SLC16A7 | |
| SCHEMBL26200805 | 0.92 | SLC16A1 (0.85) | SLC16A1CYP2C9CYP3A4SLC16A3SLC16A7 | |
| SCHEMBL3871847 | 0.92 | SLC16A1 (0.84) | SLC16A1CYP2C9CYP3A4SLC16A3SLC16A7 | |
| SCHEMBL3871850 | 0.92 | SLC16A1 (0.84) | SLC16A1CYP2C9CYP3A4SLC16A3SLC16A7 | |
| SCHEMBL3827006 | 0.91 | SLC16A1 (0.83) | SLC16A1CYP2C9CYP3A4SLC16A3SLC16A7 | |
| SCHEMBL3828110 | 0.90 | SLC16A1 (0.82) | SLC16A1CYP2C9CYP3A4SLC16A3SLC16A7 | |
| SCHEMBL3828105 | 0.90 | SLC16A1 (0.82) | SLC16A1CYP2C9CYP3A4SLC16A3SLC16A7 | |
| SCHEMBL3826387 | 0.90 | SLC16A1 (0.81) | SLC16A1CYP2C9CYP3A4SLC16A3SLC16A7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220365069-A1 | ATP-BASED CELL SORTING AND HYPERPROLIFERATIVE CANCER STEM CELLS | LUNELLA BIOTECH INC (CA) | 2022-11-17 | — | — | US | claimed |
| EP-4028509-A1 | ATP-BASED CELL SORTING AND HYPERPROLIFERATIVE CANCER STEM CELLS | Lunella Biotech, Inc. (CA) | 2022-07-20 | — | — | EP | claimed |
| CN-114630901-A | ATP-based cell sorting and hyperproliferative cancer stem cells | 卢内拉生物技术有限公司 | 2022-06-14 | — | — | CN | claimed |
| CN-114324870-A | Lung cancer biomarker targeting myeloid cell lactic acid transport signal and detection kit | 中国人民解放军空军军医大学 | 2022-04-12 | — | — | CN | claimed |
| EP-1414825-B9 | THIENOPYRIMIDINEDIONES AND THEIR USE IN THE MODULATION OF AUTOIMMUNE DISEASE | ASTRAZENECA AB (SE) | 2009-09-16 | — | — | EP | claimed |
| US-20080207642-A1 | Thienopyrimidinediones and Their Use in the Modulation of Autoimmune Disease | ASTRAZENECA AB (SE) | 2008-08-28 | — | — | US | claimed |
| US-7384950-B2 | Thienopyrimidinediones and their use in the modulation of autoimmune disease | ASTRAZENECA AB (SE) | 2008-06-10 | — | — | US | claimed |
| EP-1414825-B1 | THIENOPYRIMIDINEDIONES AND THEIR USE IN THE MODULATION OF AUTOIMMUNE DISEASE | ASTRAZENECA AB (SE) | 2007-09-26 | — | — | EP | claimed |
| US-20040254198-A1 | Thienopyrimidinediones and their use in the modulation of autoimmune disease | ASTRAZENECA AB (SE) | 2004-12-16 | — | — | US | claimed |
| US-20260115312-A1 | Conjugates for neuroretinal drug delivery | MIRECA MEDICINES GMBH (DE) | 2026-04-30 | — | — | US | disclosed |
| US-20260055062-A1 | HETEROCYCLIC INHIBITORS OF MCT4 | Vettore, LLC | 2026-02-26 | — | — | US | disclosed |
| US-12553092-B2 | Energetic cancer stem cells (E-CSCS): a new hyper-metabolic and proliferative tumor cell phenotype, driven by mitochondrial energy | LUNELLA BIOTECH, INC. (CA) | 2026-02-17 | — | — | US | disclosed |
| US-20260021165-A1 | Extracellular Carboxylesterase 2 (CES2) for the Treatment of Metabolic Disease | UNIV LELAND STANFORD JUNIOR (US) | 2026-01-22 | — | — | US | disclosed |
| EP-4658641-A1 | NOVEL COMPOUNDS THAT CAN BE USED AS THERAPEUTIC AGENTS | Xeniom GmbH (DE) | 2025-12-10 | — | — | EP | disclosed |
| US-20080207642-A1 | Thienopyrimidinediones and Their Use in the Modulation of Autoimmune Disease | ASTRAZENECA AB (SE) | 2008-08-28 | — | — | US | disclosed |
| US-7384950-B2 | Thienopyrimidinediones and their use in the modulation of autoimmune disease | ASTRAZENECA AB (SE) | 2008-06-10 | — | — | US | disclosed |
| US-7384950-B2 | Thienopyrimidinediones and their use in the modulation of autoimmune disease | ASTRAZENECA AB (SE) | 2008-06-10 | — | — | US | disclosed |
| US-7384950-B2 | Thienopyrimidinediones and their use in the modulation of autoimmune disease | ASTRAZENECA AB (SE) | 2008-06-10 | — | — | US | disclosed |
| EP-1414825-B1 | THIENOPYRIMIDINEDIONES AND THEIR USE IN THE MODULATION OF AUTOIMMUNE DISEASE | ASTRAZENECA AB (SE) | 2007-09-26 | — | — | EP | disclosed |
| US-20040254198-A1 | Thienopyrimidinediones and their use in the modulation of autoimmune disease | ASTRAZENECA AB (SE) | 2004-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260021165-A1 | Extracellular Carboxylesterase 2 (CES2) for the Treatment of Metabolic Disease | CES1, CES2, CETP | SLC16A1 1251/4885CYP2C9 970/4885CYP3A4 1064/4885 |
| US-12553092-B2 | Energetic cancer stem cells (E-CSCS): a new hyper-metabolic and proliferative tumor cell phenotype, driven by mitochondrial energy | TXNRD2, TXNRD1, TXN2 | SLC16A1 1899/4885CYP2C9 2578/4885CYP3A4 2368/4885 |
| US-20260115312-A1 | Conjugates for neuroretinal drug delivery | SLC16A1, SLC16A3, SLC16A8 | SLC16A1 1/4885CYP2C9 3845/4885CYP3A4 3448/4885 |
| US-20040254198-A1 | Thienopyrimidinediones and their use in the modulation of autoimmune disease | TPMT, CBR1, CYP2D6 | SLC16A1 3284/4885CYP2C9 89/4885CYP3A4 93/4885 |
| US-20080207642-A1 | Thienopyrimidinediones and Their Use in the Modulation of Autoimmune Disease | C5, TPMT, C9 | SLC16A1 3369/4885CYP2C9 71/4885CYP3A4 103/4885 |
| US-20260055062-A1 | HETEROCYCLIC INHIBITORS OF MCT4 | SLC16A1, SLC16A3, SLC16A7 | SLC16A1 1/4885CYP2C9 919/4885CYP3A4 586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.